Antibody delivery system for biological response modifiers
US6750329B1 · kind B1 · utility
31Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 1994 |
| Grant date | Jun 15, 2004 |
| Priority date | — |
| Expiry date | May 31, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6851
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a novel conjugate comprising an antibody directed toward a cell surface associated antigen, wherein said antigen is selected from the group consisting of 15A8 antigen and ZME-018 antigen; and a biological response modifier moiety, wherein said moiety is selected from the group consisting of TNF-alpha, TNF-beta and Interleukin-1. In addition, the present invention also provides a method of treating proliferative cell diseases comprising administration of a cytocidally effective dose of the composition of Claim 1 individual in need of said treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.